Alogliptin Benzoate: Comprehensive User Guide for Healthcare Professionals
Table of Contents
1. Product Overview & Specifications
| Parameter | Alogliptin Benzoate | Sitagliptin | Vildagliptin |
|---|---|---|---|
| CAS Number | 850649-62-6 | 486460-32-6 | 274901-16-5 |
| Bioavailability | ~100% | 87% | 85% |
| Half-Life | 21 hours | 12.4 hours | 2-3 hours |
2. Clinical Applications & Mechanism of Action
As a selective DPP-4 inhibitor, Alogliptin Benzoate demonstrates:
- GLP-1 concentration increase: 2-3 fold
- HbA1c reduction: 0.5%-0.8%
- Renal excretion: 60-70%
3. Dosage Guidelines & Administration
Recommended protocols:
| Patient Profile | Dosage | Duration |
|---|---|---|
| Normal Renal Function | 25mg/day | Chronic |
| Moderate Impairment | 12.5mg/day | Chronic |
4. Comparative Analysis with Other DPP-4 Inhibitors
| Feature | Alogliptin | Linagliptin | Saxagliptin |
|---|---|---|---|
| Cardiovascular Safety | Neutral | Neutral | Risk ↑ |
| Renal Adjustment | Required | Not Required | Required |
5. Real-World Clinical Case Studies
Case 1: Geriatric Patient Management
72-year-old female with CKD Stage 3 (eGFR 45 mL/min):
- Baseline HbA1c: 8.2%
- Post-Treatment (6 months): 7.1%
- No hypoglycemic events
6. Partner Success Stories
PharmaCorp Ltd. (Munich, Germany)
Developed fixed-dose combination with metformin:
- Formulation: 12.5mg/850mg
- Market Approval: EMA 2022
- Production Scale: 5M tablets/month
7. Request Product Documentation
Contact our regulatory specialists:
Email: info@vivalr.com
Tel: (86) 15866781826
Request:
- GMP Certification
- Stability Data
- Custom Synthesis Options


评论
目前还没有评论。